Volume 65 Received 20 January 2009 | ||||||||||
| ||||||||||
aChemistry, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, Perth 6009, Western Australia, Australia
Correspondence e-mail: brian.skelton@uwa.edu.au
The crystal structure of the title compound, C22H20N4O2P2, consists of two independent half-molecules, both of which lie on crystallographic inversion centres. There are no significant differences between the two molecules.
For the antitumour properties of metal complexes of bidentate tertiary phosphine ligands with pyridyl substituents, see: McKeage et al. (2000
); Barnard & Berners-Price (2007
); Liu et al. (2008
). The crystal structure of the parent 1,2-bis(di-2-pyridylphosphino)ethane molecule has been determined (Jones et al., 1999
). The structure of 1,2-bis(di-phenylphosphino)ethane dioxide (Calcagno et al., 2000
) is similar, with the two halves of the molecule related by a pseudo-inversion centre, but this is not isomorphous with the title compound.
|
Data collection: CrysAlis CCD (Oxford Diffraction, 2008
); cell refinement: CrysAlis RED (Oxford Diffraction, 2008
); data reduction: CrysAlis RED; program(s) used to solve structure: SIR92 (Altomare et al., 1994
); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008
); molecular graphics: ORTEPII (Johnson, 1976
); software used to prepare material for publication: publCIF (Westrip, 2009
).
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: FJ2193 ).
The authors thank the Australian Research Council for financial assistance.
Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G. & Camalli, M. (1994). J. Appl. Cryst. 27, 435.
![[details]](../../../../../../j/graphics/details.gif)
Barnard, P. J. & Berners-Price, S. J. (2007). Coord. Chem. Rev. 251, 1889-1902.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Calcagno, P., Kariuki, B. M., Kitchin, S. J., Robinson, J. M. A., Philp, D. & Harris, K. D. M. (2000). Chem. Eur. J. 6, 2338-2349.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Johnson, C. K. (1976). ORTEPII. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
Jones, N. D., MacFarlane, K. S., Smith, M. B., Schutte, R. P., Rettig, S. J. & James, B. R. (1999). Inorg. Chem. 38, 3956-3966.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Liu, J. J., Galettis, P., Farr, A., Maharaj, L., Samarasinha, H., McGechan, A. C., Baguley, B. C., Bowen, R. J., Berners-Price, S. J. & McKeage, M. J. (2008). J. Inorg. Biochem. 102, 303-310.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
McKeage, M. J., Berners-Price, S. J., Galettis, P., Bowen, R. J., Brouwer, W., Ding, L., Zhuang, L. & Baguley, B. C. (2000). Cancer Chemother. Pharmacol. 46, 343-350.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Oxford Diffraction (2008). CrysAlis CCD and CrysAlis RED. Oxford Diffraction Ltd, Abingdon, Oxfordshire, England.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
![[details]](../../../../../../a/graphics/details.gif)
Westrip, S. P. (2009). publCIF. In preparation.